Record 1 of 14642 - Inpharma DTABASE 1999-2004 / 02
TI: Product News: Cancer Vaccine Trials to Continue Following Independent Analysis.
De: caNcer-vaccom-therapeutic-use; cancervax-corporation; development-status; malignant-melanoma-treatment; research-and-development; Vaccines-therapeutic-use
TX:. CancerVax Corporation is to continue its phase III melanoma trial of its therapeutic cancer vaccine, Canvaxin, following an interim analysis by an independent Data and Safety Monitoring Board (DSMB) * The analysis was conducted using data from 842 patients enrolled in the randomised , double- blind trial, and led to the recommendation that the stage III melanoma study continue. The DSMB notes that there is a reasonable likelihood that clinical endpoints can be met to establish the effectiveness of the vaccine, and that there are no unexpected or serious THEXCITINTIME, WHICITITITIME THITIN ANTICIPATES COMPLETITYETETED TOTIME THIS.
* See 809003690
SO: CancerVax-Corporation Data and Safety Monitoring Board Recommends That CancerVax Continue Canvaxin Phase 3 Clinical Trial for Stage III Melanoma Media-Release, page 1 Mar 2004. Available from, 01 March 2004. (English, Media release (USA))..
PD: 20040301
La: eNGLISH
DT: Media-Release-USA
TA: YES
AN: 809031813
UD: 200403
Record 2 of 14642 - INPHARMA DATABASE 1999-2004 / 02
TI: Product News: CICLESONIDE Approved for Asthma In Australia.
De: Adolescents; Altana-Pharma; Asthma-Treatment; Children; Ciclesonide-Therapeutic-Use; Development-Status; Product-Approvals; Research - and-Development;
TX:. The Australian Health Agency has granted marketing approval for the inhaled corticosteroid ciclesonide (Alvesco; Altana Pharma) for the treatment of asthma in patients aged> = 12 years Altana anticipates UK approval for Alvesco by mid 2004, and notes that approval has also been sought by the company's partners, Aventis in the US and Teijin in Japan.SO:.. Altana-AG ALTANA Pharma Receives First Approval to Market Alvesco-R- -Ciclesonide Media-Release, page 27 Feb 2004. Available from, 27 February 2004. (English, Media Release (Germany))
PD: 20040227
La: eNGLISH
DT: Media-release-germany
TA: YES
AN: 809031765
UD: 200403
Record 3 of 14642 - INPHARMA DATABASE 1999-2004 / 02
TI: Product News: Topical Testosterone: Beneficial Effects in Men With hypogonadism.
De: auxilium-pharmaceutical; hypogonadism-treatment; testosterone-therapeutic-use; trial-result-clinical
TX: Topical testosterone improves sexual function, mood, body composition and bone mineral density in men with hypogonadism, according to results from a study presented at the 4th World Congress on the Aging Male held recently in Prague, with hypogonadism the Czech Republic 406 men. received topical 1% testosterone gel (Testim) or placebo, for 90 days. 290 of the men continued treatment with topical testosterone in a 12-month open-label extension of the study. Serum testosterone levels were rapidly normalised by topical testosterone. moreover, testosterone recipients demonstrated significant improvements in sexual desire and motivation, spontaneous erections, sexual performance, mood, and lean body mass during the 90-day study that were maintained throughout the extension period. in addition, there were significant improvements in bone mineral density during the Extension Phase.so: Auxilium-Pharmaceuticals-Inc. Long-Term Study Shows Use of Auxilium's Testim (R) Testosterone Gel Signif ICANTLY IMPROVES SYMPTOMS OF ERECTILE DYSFunction and low libido in men with low testosterone. Media-Release, Page 27 Feb 2004. Available from, 27 February 2004. (English, Media Release (USA))
Pd: 20040227
La: eNGLISH
DT: Media-Release-USA
TA: YES
An: 809031763
UD: 200403
Turn into Ti, de, TX ....... and other data items, please expert, thank you! In addition, if there is RTF's file format, how to convert it to the SQLServer data item.
